You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Neurological conditions
  5. Multiple sclerosis

Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis

  • Technology appraisal guidance
  • Reference number: TA254
  • Published:  25 April 2012
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Multiple sclerosis (relapsing-remitting) - fingolimod: consultee and commentator comments on the ACD

  • Multiple sclerosis (relapsing-remitting) - fingolimod: Novartis

  • Multiple sclerosis (relapsing-remitting) - fingolimod: Multiple Sclerosis Society

  • Multiple sclerosis (relapsing-remitting) - fingolimod: Multiple Sclerosis Trust

  • Multiple sclerosis (relapsing-remitting) - fingolimod: Association of British Neurologists

  • Multiple sclerosis (relapsing-remitting) - fingolimod: Royal College of Nursing

  • Multiple sclerosis (relapsing-remitting) - fingolimod: Department of Health

  • Multiple sclerosis (relapsing-remitting) - fingolimod: North Yorkshire and York PCT

  • Multiple sclerosis (relapsing-remitting) - fingolimod: NHS Centre for Reviews and Dissemination and Centre for Health Economics


This page was last updated: 15 March 2012

Back to top